Study of STAT3 Expression in Different Phases of Patients with Chronic Myeloid Leukemia
Background and Aim: Chronic myeloid leukemia(CML) is a clonal myeloproliferative disease, characterized by BCR/ABL translocation. Using tyrosine kinase inhibitors such as Imatinib, treatment for this disease has progressed remarkably. However, resistance to tyrosine kinase inhibitor is a major obsta...
Main Authors: | Peyman Yousefi, Shahrbano Rostami, Nasrin Alizadeh Ghandfurosh, Saeed Mohammadi, Mohsen Nikbakht, Laya Ghadyaninejhad, Bahram Chahardouli |
---|---|
Format: | Article |
Language: | fas |
Published: |
Tehran University of Medical Sciences
2019-07-01
|
Series: | پیاورد سلامت |
Subjects: | |
Online Access: | http://payavard.tums.ac.ir/article-1-6760-en.html |
Similar Items
-
Single Center Study of Prescribing and Treatment Outcomes of Patients with Chronic Myeloid Leukemia
by: Ladan Nekoohesh, et al.
Published: (2020-01-01) -
IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
by: Tomasz Sacha
Published: (2013-12-01) -
Curcumin Combined with Thalidomide Reduces Expression of STAT3 and Bcl-xL, Leading to Apoptosis in Acute Myeloid Leukemia Cell Lines
by: Mohammadi Kian M, et al.
Published: (2020-01-01) -
Chronic myeloid leukemia and ferritin levels
by: Kumar Saurabh, et al.
Published: (2017-01-01) -
Hematologic Relapse after 2 Years on a Non-Authorized Copy Version of Imatinib in a Patient with Chronic Myeloid Leukemia in Chronic Phase: A Case Report
by: Zoubir Chouffai
Published: (2010-07-01)